Eurofins DiscoverX Revenue and Competitors

Location

$18.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Eurofins DiscoverX's estimated annual revenue is currently $29.8M per year.(i)
  • Eurofins DiscoverX's estimated revenue per employee is $193,750
  • Eurofins DiscoverX's total funding is $18.4M.

Employee Data

  • Eurofins DiscoverX has 154 Employees.(i)
  • Eurofins DiscoverX grew their employee count by -3% last year.

Eurofins DiscoverX's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$41.9M270-2%N/AN/A
Add Company

What Is Eurofins DiscoverX?

DiscoveRx' proprietary technology platform is comprised of fluorescence and chemiluminescence-based technologies designed to provide flexible, high throughput, cost-effective solutions to the current and evolving HTS requirements of drug discovery laboratories. DiscoveRx uses its' proprietary position in homogeneous, high sensitivity, biological assays to be the first to market with effective solutions to the problems facing HTS users.

keywords:N/A

$18.4M

Total Funding

154

Number of Employees

$29.8M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Eurofins DiscoverX News

2022-04-20 - Cell-Based Drug Discovery Services Market Size, Scope And ...

Thermo Fisher Scientific, Wuxi Apptec, Syngene International Limited, Lonza Group, Eurofins DiscoverX. This Cell-Based Drug Discovery...

2022-04-17 - Global Cell-Based Assay market is projected to reach at a

For instance, in February 2020, Eurofins DiscoverX, the products company of Eurofins Discovery announced their partnership with VelaLabs of...

2022-04-13 - An efficient and effective PIM3 kinase-focused screening ...

To overcome these limitations, over the last decade Eurofins Discovery ... PIM3 kinase produced by Eurofins DiscoverX™) as well as confirmation and ranking...

2007-03-26 - DiscoveRX raises $5M more for drug research technology

DiscoveRx, a Fremont, Calif. company that offers biochemical and cell-based assays to make drug research more efficient, has raised $5 million more to its second round of funding, VentureWire reports (sub required). This adds to $21.2 previously raised in 2000 and 2002. Ivestors included previ ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.6M1543%N/A
#2
$24.9M15610%N/A
#3
$24.9M156N/AN/A
#4
$56.1M1571%N/A
#5
$25M157N/AN/A